Providers use many frequently prescribed drugs across disease states without a clear understanding of their mechanisms. In treating breast cancer, there is not always a full understanding of HER2 testing, which is now standard practice for women with breast cancer. This activity will educate oncology nurses and other APs about the potential benefits of neoadjuvant therapy for HER2-positive breast cancer, the scientific basis for new HER2-targeted treatments that could improve neoadjuvant responses and/or tumor resectability, and in many cases educate patients and support them in the decision process.